COM:ENOCHIANBIO
Renovaro Biosciences
- Stock
Last Close
0.70
04/08 19:58
Market Cap
45.38M
Beta: -
Volume Today
87.29K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '14 | Jun '16 | Jun '17 | Jun '18 | Jun '19 | Jun '20 | Jun '21 | Jun '22 | ||
|---|---|---|---|---|---|---|---|---|---|
average inventory | |||||||||
average payables | 1.05M - | 927.54K 12.04% | 738.39K 20.39% | 672.69K 8.90% | 565.72K 15.90% | 456.72K 19.27% | 861.21K 88.57% | ||
average receivables | 351.72K - | 459.60K 30.67% | 173.32K 62.29% | 71.83K 58.56% | 11.39K 84.15% | 1.81K 84.10% | 820 54.72% | ||
book value per share | 0.46 - | -0.07 114.40% | 0.12 286.89% | 7.11 5,586.50% | 4.61 35.13% | 3.59 22.14% | 3.70 3.18% | 1.38 62.67% | |
capex per share | -0.00 - | -0.02 1,295.76% | -0.00 79.14% | -0.00 73.97% | -0.00 90.53% | ||||
capex to depreciation | -0.01 - | -9.99 95,127.86% | -1.70 83.00% | -0.12 92.65% | -0.04 66.60% | ||||
capex to operating cash flow | 0.01 - | 0.08 1,118.20% | 0.02 79.06% | 0.00 86.55% | 0.00 86.18% | ||||
capex to revenue | |||||||||
cash per share | 0.40 - | 0.00 99.39% | 0.32 13,009.54% | 0.71 121.28% | 0.33 54.00% | 0.19 42.61% | 0.44 133.41% | 0.17 60.14% | |
days of inventory on hand | |||||||||
days payables outstanding | 1.14K - | 82.00K 7,089.74% | |||||||
days sales outstanding | 5.93K - | ||||||||
debt to assets | 0.02 - | 0.12 519.36% | 0.46 291.17% | 0.04 - | 0.04 9.45% | 0.08 115.01% | |||
debt to equity | 0.03 - | -0.16 662.34% | 1.36 944.73% | 0.05 - | 0.04 8.23% | 0.10 130.84% | |||
dividend yield | |||||||||
earnings yield | -0.05 - | -0.07 38.19% | -0.10 41.01% | -0.13 22.37% | -0.15 19.36% | -0.06 60.61% | -0.11 93.01% | -1.12 881.51% | |
enterprise value | 42.09M - | 23.91M 43.19% | 21.45M 10.28% | 57.24M 166.81% | 155.20M 171.13% | 193.94M 24.96% | 221.07M 13.99% | 99.22M 55.12% | |
enterprise value over ebitda | -17.70 - | -11.42 35.47% | -8.14 28.74% | -10.87 33.57% | -14.31 31.63% | -16.48 15.19% | -9.61 41.69% | -4.39 54.29% | |
ev to operating cash flow | -20.69 - | -16.24 21.51% | -18.22 12.18% | -13.19 27.58% | -18.24 38.26% | -18.54 1.64% | -10.73 42.15% | -6.31 41.20% | |
ev to sales | 559.11 - | ||||||||
free cash flow per share | -0.27 - | -0.15 43.06% | -0.10 37.84% | -0.20 107.41% | -0.25 23.37% | -0.23 6.47% | -0.44 90.66% | -0.30 31.60% | |
free cash flow yield | -0.05 - | -0.06 36.66% | -0.05 18.22% | -0.06 18.70% | -0.06 8.16% | -0.05 0.92% | -0.09 61.50% | -0.16 76.14% | |
graham net net | 0.17 - | -0.10 160.28% | 0.09 190.37% | -0.37 502.88% | 0.15 139.96% | -0.07 145.98% | 0.12 279.50% | -0.05 144.58% | |
graham number | 1.82 - | 0.52 71.20% | 0.74 41.52% | 8.17 1,002.70% | 8.33 1.99% | 4.48 46.20% | 6.87 53.33% | 8.20 19.29% | |
income quality | 0.86 - | 0.85 1.11% | 0.49 42.00% | 0.47 3.67% | 0.47 0.39% | 0.92 94.02% | 0.77 15.82% | 0.14 82.02% | |
intangibles to total assets | 0.04 - | 0.16 338.16% | 0.03 82.35% | 0.91 3,213.10% | 0.93 1.60% | 0.94 0.99% | 0.88 6.07% | 0.87 1.45% | |
interest coverage | -28.73 - | -897.18 3,022.66% | -100.93 88.75% | -57.02 43.50% | -255.58K 448,101.73% | -114.34 99.96% | -61.65 46.09% | -311.33 405.03% | |
interest debt per share | 0.02 - | 0.01 55.12% | 0.17 1,462.63% | 0.01 96.21% | 0.00 99.98% | 0.17 14,491,516.87% | 0.16 1.74% | 0.14 13.72% | |
inventory turnover | |||||||||
invested capital | 0.03 - | -0.16 662.34% | 1.36 944.73% | 0.05 - | 0.04 8.23% | 0.10 130.84% | |||
market cap | 45.00M - | 23.83M 47.04% | 23.31M 2.21% | 72.84M 212.54% | 167.48M 129.92% | 195.05M 16.46% | 234.42M 20.18% | 101.38M 56.75% | |
net current asset value | 3.29M - | -775.75K 123.59% | 1.21M 255.91% | -8.00M 761.67% | 5.72M 171.45% | -2.89M 150.52% | 5.96M 306.22% | -2.45M 141.11% | |
net debt to ebitda | 1.22 - | -0.04 103.11% | 0.70 1,949.77% | 2.96 321.76% | 1.13 61.78% | 0.09 91.65% | 0.58 514.05% | 0.10 83.56% | |
net income per share | -0.32 - | -0.18 42.42% | -0.20 7.17% | -0.42 113.83% | -0.67 60.35% | -0.25 62.82% | -0.57 127.85% | -2.16 281.15% | |
operating cash flow per share | -0.27 - | -0.15 43.06% | -0.10 37.84% | -0.20 105.99% | -0.23 14.58% | -0.23 0.35% | -0.44 93.56% | -0.30 31.46% | |
payables turnover | 0.32 - | 0.00 98.61% | |||||||
receivables turnover | 0.06 - | ||||||||
research and ddevelopement to revenue | 18.80 - | ||||||||
return on tangible assets | -0.47 - | -2.36 403.15% | -0.54 76.95% | -0.57 5.61% | -1.89 228.15% | -1.00 47.15% | -1.16 16.21% | -9.97 760.90% | |
revenue per share | 0.00 - | ||||||||
roe | -0.68 - | 2.72 499.85% | -1.56 157.35% | -0.06 96.24% | -0.15 147.17% | -0.07 52.25% | -0.15 120.82% | -1.56 920.93% | |
roic | -0.63 - | 3.13 596.52% | -0.71 122.74% | -0.05 92.73% | -0.09 70.97% | -0.07 22.61% | -0.13 85.30% | -1.44 1,030.77% | |
sales general and administrative to revenue | 31.02 - | ||||||||
shareholders equity per share | 0.46 - | -0.07 114.40% | 0.12 286.89% | 7.11 5,586.50% | 4.61 35.13% | 3.59 22.14% | 3.70 3.18% | 1.38 62.67% | |
stock based compensation to revenue | |||||||||
tangible asset value | 3.30M - | -773.14K 123.46% | 1.41M 282.16% | -7.84M 656.52% | 6.54M 183.48% | -269.06K 104.11% | 8.13M 3,122.74% | -636.42K 107.83% | |
tangible book value per share | 0.44 - | -0.08 118.46% | 0.11 241.57% | -0.36 411.14% | 0.17 148.77% | -0.01 103.33% | 0.17 3,069.13% | -0.01 107.03% | |
working capital | 3.29M - | -775.75K 123.59% | 1.21M 255.91% | 14.89M 1,130.98% | 11.38M 23.53% | 7.61M 33.19% | 19.01M 149.96% | 3.11M 83.62% |
All numbers in (except ratios and percentages)